Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3107472 22 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Malignant pleural mesothelioma is resistant to currently used treatment. Angiopoieitn-1 directly promotes mesothelioma cell growth in a Tie-2-dependent fashion. Angiopoietin/Tie-2 axis may thus be valid targets for therapeutic interventions against mesothelioma. We hypothesized that a soluble angiopoietin inhibitor (Murine Tek-deltaFc) would halt mesothelioma progression in vivo by enhancing mesothelioma cell proliferation and inhibiting tumor angiogenesis. Our hypothesis was challenged on two syngeneic mesothelioma in vivo models (AB1 cells- Balb/c mice and AE17 cells-C57BL/6 mice. Even though both mesothelioma cell lines express the Angiopoietin-1/-2 and Tie-2, murine Tek-deltaFc hampered AB1 but not AE17 mesothelioma growth in vivo by enhancing tumor cell apoptosis and limiting tumor angiogenesis. Neither angiopoietins (Angs)-1 and -2 nor the inhibitor affected mesothelioma cell growth in vitro. AB1 (responding) tumors were more vascularized and displayed higher endothelial Tie-2 and lower tumor Ang-1 expression than the (non-responding) AE17 tumors. Angiopoietins-1 and -2 are expressed in tumors and pleural cavity of mesothelioma patients demonstrating the clinical relevance of our experimental observations. In conclusion, disrupting Ang-Tie-2 signaling limits mesothelioma angiogenesis and halts tumor progression. Tumor vascularity, endothelial Tie-2 expression and tumor Ang-1 expression may predict mesothelioma response to Tek-deltaFc. © Magkouta et al.
Έτος δημοσίευσης:
2018
Συγγραφείς:
Magkouta, S.
Pappas, A.
Pateras, I.S.
Kollintza, A.
Moschos, C.
Vazakidou, M.-E.
Karavana, V.
Gorgoulis, V.G.
Kalomenidis, I.
Περιοδικό:
OncoTargets and therapy
Εκδότης:
Impact Journals, LLC
Τόμος:
9
Αριθμός / τεύχος:
31
Σελίδες:
21783-21796
Επίσημο URL (Εκδότης):
DOI:
10.18632/oncotarget.25004
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.